SMOC1

SMOC1 is a secreted matricellular glycoprotein that modulates BMP and TGF-β signaling to control skeletal, ocular, limb, vascular, and metabolic development and homeostasis. It localizes to basement membranes via its calcium-dependent conformation and mediates cell adhesion through heparin/heparan sulfate binding in its EC domain (PMID:12130637, PMID:23437253); it forms a ternary complex by simultaneously binding BMP ligands and glypicans, thereby tuning BMP pathway output both positively and negatively depending on context, while also antagonizing ALK5/SMAD2-dependent TGF-β signaling through association with endoglin (PMID:37590248, PMID:25750188). Loss-of-function mutations cause ophthalmo-acromelic syndrome, with absence of the fibula, syndactyly from impaired interdigital apoptosis, and optic nerve aplasia, reflecting essential BMP-dependent roles in limb and eye patterning (PMID:21194678, PMID:21750680). SMOC1 also functions as a glucose-responsive hepatokine that suppresses hepatic gluconeogenesis by inhibiting cAMP-PKA-CREB signaling, and its overexpression in pancreatic β-cells promotes dedifferentiation and reduces insulin secretion (PMID:32878981, PMID:41057332).

1. 2002 High

   Establishing the molecular identity of SMOC1 as a secreted, calcium-dependent glycoprotein residing in basement membranes resolved where this novel SPARC-family member acts and what structural features (EF-hand, follistatin-like, thyroglobulin-like domains) might mediate its signaling functions.

   Evidence Recombinant expression, immunogold EM, Northern blot, and biochemical characterization in human cells

   PMID:12130637

   Open questions at the time

   • No signaling pathway placement
   • Biological function in vivo unknown
   • Binding partners unidentified
2. 2009 High

   Demonstrating that SMOC1 antagonizes BMP signaling downstream of the receptor via MAPK-mediated Smad linker phosphorylation in Xenopus placed SMOC1 mechanistically within the BMP pathway and showed it was essential for post-gastrulation development.

   Evidence Gain-of-function with constitutively active BMP receptor, morpholino knockdown, Xenopus embryo assays

   PMID:19414592

   Open questions at the time

   • Intracellular BMP antagonism mechanism not confirmed in mammals
   • Direct molecular target of SMOC1 in MAPK activation unidentified
   • No in vivo mammalian loss-of-function
3. 2010 High

   Generation of Smoc1 knockout mice revealed essential non-redundant roles in ocular and limb morphogenesis — optic nerve aplasia, syndactyly from failed interdigital apoptosis, and fibular defects — linking the BMP-antagonist function to specific developmental processes.

   Evidence Smoc1 knockout mouse, histology, BMP target gene expression in interdigital mesenchyme

   PMID:21194678

   Open questions at the time

   • Whether SMOC1 acts extracellularly or intracellularly on BMP in mammals unresolved
   • Molecular partners at the limb/eye level unknown
   • Redundancy with SMOC2 not tested
4. 2011 High

   Identification of pathogenic missense mutations in the second thyroglobulin type-1 domain in patients with ophthalmo-acromelic syndrome established SMOC1 as a Mendelian disease gene and pinpointed a critical domain for BMP antagonism.

   Evidence Homozygosity mapping, targeted mutation analysis, gene-trap mouse phenotyping

   PMID:21750680

   Open questions at the time

   • Structure of TG1 domain and how mutations disrupt BMP antagonism unknown
   • Genotype-phenotype correlations incomplete
5. 2011 High

   Quantitative demonstration that SMOC1 binds tenascin-C with nanomolar affinity in a calcium-dependent manner, and counteracts tenascin-C-driven glioma cell migration, identified a direct extracellular matrix partner and an anti-migratory function.

   Evidence SPR (Kd ~2.59 nM), co-immunoprecipitation, affinity column, cell migration assay

   PMID:21349332

   Open questions at the time

   • In vivo relevance of tenascin-C interaction for development or disease not tested
   • Binding domain on SMOC1 not mapped
6. 2013 High

   Mapping the heparin/heparan sulfate-binding site to two antiparallel α-helices in the EC domain and showing that this interaction is required for epithelial cell adhesion established the structural basis of SMOC1's matricellular adhesion function.

   Evidence Tryptophan fluorescence binding assay, site-directed mutagenesis, HaCaT cell adhesion assay

   PMID:23437253

   Open questions at the time

   • Identity of the cell-surface heparan sulfate proteoglycan receptor unknown
   • Whether the EC domain mediates adhesion in vivo untested
7. 2015 High

   Showing that SMOC1 associates with endoglin and suppresses ALK5/SMAD2 signaling to favor ALK1-dependent endothelial proliferation and angiogenesis revealed a second signaling axis — TGF-β pathway modulation — distinct from BMP antagonism.

   Evidence Proximity ligation assay, co-IP, siRNA, in vitro/ex vivo angiogenesis, SMOC1+/− retinal angiogenesis in vivo

   PMID:25750188

   Open questions at the time

   • Whether SMOC1-endoglin interaction is direct or bridged unclear
   • Structural basis of ALK5 vs ALK1 pathway selection unknown
8. 2018 High

   Genetic epistasis in C. elegans showed SMOC-1 acts cell non-autonomously as a positive BMP modulator by antagonizing the glypican LON-2 and requiring BMP ligand DBL-1, and human SMOC1 rescued the worm mutant, demonstrating deep evolutionary conservation.

   Evidence Genetic double-mutant analysis, BMP reporter assay, rescue with human SMOC1/SMOC2

   PMID:30518528

   Open questions at the time

   • Physical interaction between SMOC-1, LON-2, and DBL-1 not biochemically demonstrated
   • Mechanism of dual positive/negative regulation unclear
9. 2020 High

   Identification of SMOC1 as a glucose-responsive hepatokine that suppresses gluconeogenesis by inhibiting cAMP-PKA-CREB signaling expanded its biology from developmental signaling to metabolic homeostasis and suggested therapeutic potential.

   Evidence Liver-specific overexpression, SMOC1-Fc fusion protein injection in db/db mice, hepatic cAMP-PKA-CREB pathway analysis

   PMID:32878981

   Open questions at the time

   • Cell-surface receptor for SMOC1 in hepatocytes unknown
   • Mechanism of cAMP-PKA inhibition not defined
   • Whether metabolic and BMP functions are linked unknown
10. 2021 High

    Demonstration that Smoc1 and Smoc2 are transcriptional targets of Runx2, and that double knockout causes severe skeletal defects exceeding those of single knockouts, established transcriptional regulation and functional redundancy in osteogenesis.

    Evidence RNA-seq for Runx2 targets, Smoc1 KO and Smoc1/Smoc2 double KO mice, siRNA osteoblastogenesis assay

    PMID:34667264

    Open questions at the time

    • Direct Runx2 binding to Smoc1 promoter not shown by ChIP
    • Whether redundancy is quantitative or through distinct mechanisms unknown
11. 2023 High

    Biochemical reconstitution of a ternary SMOC-1/glypican/BMP complex — with the EC domain binding glypican and full-length SMOC-1 required for BMP binding — resolved the long-standing question of how SMOC1 simultaneously exerts positive (BMP-dependent) and negative (glypican-dependent) effects on BMP signaling.

    Evidence Co-IP, domain-specific mutant analysis, structural modeling, genetic epistasis in C. elegans

    PMID:37590248

    Open questions at the time

    • No high-resolution structure of the ternary complex
    • Vertebrate ternary complex formation not biochemically validated
    • Stoichiometry and affinity of each interaction not quantified
12. 2025 Medium

    Overexpression studies linking SMOC1 to β-cell dedifferentiation and reduced insulin secretion extended SMOC1's metabolic roles to pancreatic islet biology and type 2 diabetes pathogenesis.

    Evidence Single-cell/single-nucleus RNA-seq, SMOC1 overexpression in β-cells with insulin secretion and dedifferentiation marker readouts

    PMID:41057332

    Open questions at the time

    • Loss-of-function in β-cells not tested
    • Signaling pathway mediating β-cell dedifferentiation unidentified
    • In vivo β-cell-specific manipulation not performed

• The cell-surface receptor through which secreted SMOC1 signals in hepatocytes and β-cells, the high-resolution structure of the SMOC1-BMP-glypican ternary complex, and whether the developmental BMP-modulatory and metabolic cAMP-inhibitory functions share a common signaling entry point remain unknown.
• No SMOC1 receptor identified in any metabolic tissue
• No crystal/cryo-EM structure of SMOC1 or its complexes
• Relationship between BMP and cAMP-PKA axes unexplored